Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
With Obamacare premium hikes, more people opting for no coverage or cheaper plans - 2From invasive species tracking to water security – what’s lost with federal funding cuts at US Climate Adaptation Science Centers
- 3Former hostage Eitan Mor on Hamas: ‘They will not give up until the last Israeli is gone'
- 4Find the Future of Outsourcing: Exploring the Gig Economy
- 5The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree
- Two separate Israeli espionage cases uncover Iran-linked activities in Jerusalem, Ashkelon
- Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- ISS astronaut snaps stunning nighttime photo of Florida and Cuba | Space photo of the day for Dec. 29, 2025
- Hezbollah fires over 600 times at Israel, IDF troops over last 24 hours
- PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds
- 4 astronauts are now on their path to the moon. Here’s what happens next
- Astronomer captures 2 meteors slamming into the moon (video)
- Gartex Texprocess India to showcase innovations across textile ecosystem
- Culinary Joys: Investigating Connoisseur Cooking at Home
